Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03247829 · ClinicalTrials.gov registry record
Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™
A clinical trial, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 101
- Enrollment target
NCT03247829: Completed study, sponsored by Abbott Medical Devices.
NCT03247829 is a clinical trial that has completed, run by Abbott Medical Devices. The registered enrollment target is 101 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03247829 has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 101 participants
- Enrollment target
Study Summary
This observational post market study is intended to characterize hemodynamic-guided management of patients with an existing left ventricular assist device (LVAD) to protocol specified target ranges and its impact on functional status, quality of life, and readmissions
Primary Outcome
Change in 6MHW distance compared to baseline. The six-minute hall walk (6MHW) test measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.
Interventions
- DEVICE Hemodynamic management using CardioMEMS HF System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2017-08-24 |
| Est. Completion | 2020-06-30 |
What the finished NCT03247829 record still lists
NCT03247829 is an observational study that tracks outcomes without assigning an intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Hemodynamic management using CardioMEMS HF System is the first listed.
NCT03247829 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03247829 about?
NCT03247829 is a clinical study titled "Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™". This observational post market study is intended to characterize hemodynamic-guided management of patients with an existing left ventricular assist device (LVAD) to protocol specified target ranges and its impact on functional status, quality of life, and readmissions
What is the current status of trial NCT03247829?
This trial is currently completed. The enrollment target is 101 participants. The study started on 2017-08-24. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03247829?
The interventions under investigation include: Hemodynamic management using CardioMEMS HF System (DEVICE).
Who is sponsoring clinical trial NCT03247829?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI